Q: My first reaction to the big deal announced this morning was to sell all my shares. I don’t understand buying a company for so much that is ebitda breakeven. I realize the recurring revenue is good and maybe this gives them cross selling opportunities but will this deal not result in diluted eps and ebitda/share? What’s your take on he deal? Thanks
Q: Sangoma announced a major deal this morning. On the investor call, Management gave out fiscal 2020 EBITDA margin forecast of 13% based on at least $100M sales for the combined companies. (Of note Sangoma has a habit of beating its forward guidance.) What EBITDA multiple should STC trade at now?
Q: I am buying a few junior uranium companies as speculations. Can you tell me a bit about this company's cash position, debt, cash burn, and how long it could survive until the uranium market improves? Any other comments you have would also be very much appreciated. Thank you so much.
Q: Please your comments on recent results & signed agreement for 10k Mobile-10T solutions unit.Does management still own some 30%?Thanks for u usual great services & views
Q: Recently Benj Gallagher was on Mike Campbell’s Money Talks. I don’t subscribe to the idea of being a contrarian just for the sake of being different, but I do believe there can be great buying opportunities for pretty much anything when it becomes oversold or out of favour. Benj mentioned that Quarterhill and GMP were two of his favorites looking forward. This was based on suffering substantial drops recently, having little to no debt, good cash flow and reserves and good management. Do you agree that these two meet those criteria? what do you think about them looking forward? Even if they rebounded close to their 52 week highs it would mean substantial gains.
Thanks
Q: Company gave the higher input cost and transportation as the reason of lower profit in 2Q-2018 and the stock fall 15% to 18%. Is this a concern for future or there is some thing more which pushed the price lower? Do you recommend adding to the position? It weights less than 1% of my portfolio.
Q: Do you think this one has turned the business around - is it time to reinvest and do you think the dividend is safe. I am wondering about the impact on CLCT with the Asian slowdown.
Q: these mittleman brothers with an 18% stake in aimia put out a press release saying the nav of aimia is 7.50 a share, and they release a sum of the parts,the stock closed at 4.30. is this realistic or just pie in the sky. dave
Q: Similar to Dave I am having trouble assessing the value of Aimia and specifically assessing expected tax impacts of the sale of Aeroplan. Aimia's largest shareholder (Mittleman Brothers LLC) issued a statement supporting the recent offer - however, in this statement it notes expected taxes on the sale should be minimal - can you please confirm this?
The statement also notes that their "sum of the parts" valuation for Aimia is C$7.50 per share. This is based on a "full valuation" for PLM Premier - however, even discounting that to the recent offer received the valuation is closer to C$5 per share. Also no value is being assigned to potential tax losses that could be carried forward.
What is driving the substantial discount in the share price? Does 5i have a view on what the "fair value" of Aimia is based on the revised Aeroplan offer?
Q: My question is on VIVO. It's a rebrand from former Abcann Global and apparently your system has not yet updated so I couldn't put it into the box above. Just wondering if you have any further insights in regard to this stock. I recognize that it is just one more entry in a large field of cannabis "wannabees". They suggest on their website that they have some proprietary technology in regard to cannabis production that might give them an advantage but I'm not sure how much credence to put in this claim. Generally, please give your opinion on VIVO currently in regard to valuation, management and forward guidance, to the extent that you are able. Also, do they have any free cash flow at the moment and what is their debt level like. Thanks.